Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Lymphoblastic LymphomaNHL, T-Cell Type, Lymphoblastic LymphomaSubgroupB-ALLPh/BCR-ABL+Ph/BCR-ABL-T-ALLICD10C83.5C83.7C84.6C91.0-MeSHPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceGMALL 08/2013-ALL/LBL, 56 - 75GMALL 08/2013-ALL/LBL, 56 - 75, Ph/BCR-ABL+GMALL 08/2013-ALL/LBL 18 - 55GMALL 08/2013-ALL/LBL 18 - 55, Ph/BCR-ABL+GMALL 08/2013-B-ALL/NHL 2002 Regimen, 18 - 55GMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, B-ALL onlyGMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, NHL onlyChemotherapyChemo-substanceCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinEtoposideIdarubicinMercaptopurineMethotrexateNelarabinePeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinEtoposideIdarubicinMercaptopurineMethotrexateNelarabinePeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinEtoposideIdarubicinMercaptopurineMethotrexateNelarabinePeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinEtoposideIdarubicinMercaptopurineMethotrexateNelarabinePeg asparaginasePrednisoloneRituximabVincristineVindesineNo. Substances12345678 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateNo. Substances4589101116Protocol classificationTherapy classificationcurrent standardStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineRelapse therapyTherapy phaseConsolidationInductionPre-phaseReinductionTherapy intentioncurativecurative or palliativeRisksAnemia Hb below 8g/dlAstheniaDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHypertensionIncrease AminotransferasesInfectionsMyalgiasNeuropathyNeutropeniaSeizuresThrombocytopenia below 50 000/µl only studiesPublicationAuthorDeAngelo DJGökbuget DGökbuget NHoelzer DDiseaseAkute lymphatische Leukämie, lymphoblastische Lymphome, 18-55 JahreAkute lymphatische Leukämie, lymphoblastische Lymphome, 56-75 JahreAkute lymphatische Leukämie, lymphoblastische Lymphome, Therapieversagen oder MRD-Persistenz nach Konsolidation I,18-55 JahreHochmaligne B-ALL und B-NHL bei Erwachsenen, ErstlinieT-ALL/LBL, therapierefraktär oder rezidiviertOriginDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Cancer and Leukemia Group B study 19801German Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaGerman Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, GMALL 07/2017Protocols in Revision 18 protocols foundProtocols under revision.GMALL 08/2013 - ALL/LBL consolidation III and V (weeks 24, 32), 18 - 55 years (PID634 V2.0)GMALL 08/2013 - ALL/LBL Induction I (Day 6), 18 - 55 years, all risk groups (PID592 V2.0)GMALL 08/2013 - ALL/LBL Induction I (Day 6), 56 - 75 years (PID1087 V1.1)GMALL 08/2013 - ALL/LBL Induction II (Day 20), 56 - 75 years (PID1088 V1.1)GMALL 08/2013 - ALL/LBL Induction II (Day 23), 18 - 55 years, all risk groups (PID594 V2.0)GMALL 08/2013 - ALL/LBL consolidation I (day 60), 18 - 55 years, all risk groups (PID595 V3.0)GMALL 08/2013 - ALL/LBL Consolidation I (Week 9), 56 - 75 years (PID1086 V1.0)GMALL 08/2013 - ALL/LBL Consolidation II (Week 14), 18 - 55 years (PID1098 V1.0)GMALL 08/2013 - ALL/LBL Consolidation II (Week 15), 56 - 75 years (PID1091 V1.1)GMALL 08/2013 - ALL/LBL consolidation II in treatment failure/MRD persistence of T-ALL/T-LBL, 18 - 55 years (PID965 V2.0)GMALL 08/2013 - ALL/LBL consolidation III and V (week 24,34), 56 - 75 yrs (PID1090 V1.1)GMALL 08/2013 - ALL/LBL consolidation IV and VI (weeks 27, 35), 18 - 55 yrs (PID632 V2.1)GMALL 08/2013 - ALL/LBL Reinduction (Week 19), 18 - 55 years (PID636 V2.1)GMALL 08/2013 - ALL/LBL Reinduction (Week 19), 56 - 75 years (PID1096 V1.1)GMALL 08/2013 - ALL/LBL Pre-phase, 18 - 55 yrs (PID591 V2.0)GMALL 08/2013 - ALL/LBL Pre-phase, 56 - 75 yrs (PID1085 V1.0)GMALL 08/2013 - B-ALL/NHL 2002 regimen, Rituximab consolidation (PID784 V1.0)Nelarabine 1500, T-ALL/T-LBL (PID1922 V1.0)
